APA (7th ed.) Citation

Bauhammer, J., Blank, N., Max, R., Lorenz, H., Wagner, U., Krause, D., & Fiehn, C. (2016). Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. Journal of rheumatology, 43(8), 1566. https://doi.org/10.3899/jrheum.150844

Chicago Style (17th ed.) Citation

Bauhammer, Jutta, Norbert Blank, Regina Max, Hanns-Martin Lorenz, Ulrich Wagner, Dietmar Krause, and Christoph Fiehn. "Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response." Journal of Rheumatology 43, no. 8 (2016): 1566. https://doi.org/10.3899/jrheum.150844.

MLA (9th ed.) Citation

Bauhammer, Jutta, et al. "Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response." Journal of Rheumatology, vol. 43, no. 8, 2016, p. 1566, https://doi.org/10.3899/jrheum.150844.